Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon
Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, et al.
Cytokine & Growth Factor Reviews (2021) Vol. 60, pp. 28-45
Open Access | Times Cited: 23

Showing 23 citing articles:

The crucial regulatory role of type I interferon in inflammatory diseases
Ling Ji, Tianle Li, Huimin Chen, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 32
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells
Xiaodong Zhuang, Senko Tsukuda, Florian Wrensch, et al.
iScience (2021) Vol. 24, Iss. 10, pp. 103144-103144
Open Access | Times Cited: 51
Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes
Cheng‐Han Chen, Sheng-Wen Lin, Ching‐Fen Shen, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 509-509
Open Access | Times Cited: 36
Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection
Grigore Mihăescu, Mariana Carmen Chifiriuc, Roxana Filip, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 8
Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review
Ling‐Ying Lu, Po‐Hao Feng, Ming‐Sun Yu, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 63, pp. 34-43
Open Access | Times Cited: 20
The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity
Po‐Ku Chen, Kai‐Jieh Yeo, Shih‐Hsin Chang, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 13
Guardians at the gate: Unraveling Type I interferon’s role and challenges posed by anti-interferon antibodies in COVID-19
Alaa A. A. Aljabali, Mohammad A. Obeid, Omar Gammoh, et al.
Progress in molecular biology and translational science (2025)
Closed Access
The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2
Saba R. Aliyari, Natalie Quanquin, Olivier Pernet, et al.
Pathogens (2022) Vol. 11, Iss. 5, pp. 538-538
Open Access | Times Cited: 12
Immunouniverse of SARS-CoV-2
Dennis Jiménez, Marbel Torres Arias
Immunological Medicine (2022) Vol. 45, Iss. 4, pp. 186-224
Open Access | Times Cited: 12
Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far
Md. Jamal Hossain, Tabassum Jannat, Shejuti Rahman Brishty, et al.
Biologics (2021) Vol. 1, Iss. 2, pp. 252-284
Open Access | Times Cited: 15
Comparing the effects of three decoctions for coronavirus disease 2019 on severe acute respiratory syndrome coronavirus 2-related toll-like receptors-mediated inflammations.
L I Ximeng, Kang Yuan, L I Wenjing, et al.
PubMed (2023) Vol. 43, Iss. 1, pp. 51-59
Closed Access | Times Cited: 6
Association between Statins Administration and Influenza Susceptibility: A Systematic Review and Meta-Analysis of Longitudinal Studies
Fan Wu, Congcong Wang, Shunran Li, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Pharmacological therapies and drug development targeting SARS-CoV-2 infection
Yi‐Zhou Jiang, Limor Rubin, Zhiwei Zhou, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 68, pp. 13-24
Open Access | Times Cited: 10
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios
Francesca Palandri, Massimo Breccia, Valerio De Stefano, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4750-4750
Open Access | Times Cited: 11
Insights on interferon-independent induction of interferon-stimulated genes shaping the lung's response in early SARS-CoV-2 infection
Sung‐Dong Cho, Haeun Shin, Su-Jin Kim, et al.
Heliyon (2023) Vol. 9, Iss. 12, pp. e22997-e22997
Open Access | Times Cited: 4
Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role
Moayed Ben Moftah, Asma Eswayah
Assay and Drug Development Technologies (2022) Vol. 20, Iss. 1, pp. 55-62
Closed Access | Times Cited: 6
Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5495-5495
Open Access | Times Cited: 5
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells
Xiaodong Zhuang, Senko Tsukuda, Florian Wrensch, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 6
SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale
Dominic Worku
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3228-3228
Open Access | Times Cited: 4
Potential network markers and signaling pathways for B cells of COVID-19 based on single-cell condition-specific networks
Ying Li, Liqin Han, Peiluan Li, et al.
BMC Genomics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Immune network operations in COVID-19
Javier Burgos-Salcedo
Exploration of Immunology (2022), pp. 572-580
Open Access | Times Cited: 2
In silicoandin vitrostudies on inhibitors for SARS-CoV-2 non-structural proteins with dual herbal combination ofWithania somniferawith five rasayana herbs
Srinivasan Bhargavi, S. R. Madhan Shankar, Jemmy Christy
Journal of Biomolecular Structure and Dynamics (2022) Vol. 41, Iss. 8, pp. 3265-3280
Closed Access | Times Cited: 1
Modeling COVID-19 disease biology to identify drug treatment candidates
Walter J. Jessen, Stefan Diaz Gaisenband, M’Lissa Quintanilla, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top